Advertisement
Advertisement
U.S. markets open in 7 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioCorRx Inc. (BICX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.0500+0.1600 (+8.47%)
At close: 01:26PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8900
Open2.0875
BidN/A x N/A
AskN/A x N/A
Day's Range2.0500 - 2.0875
52 Week Range1.0000 - 7.5000
Volume1,672
Avg. Volume661
Market Cap14.527M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-0.6900
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BICX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BIOCORRX INC
    Analyst Report: The Procter & Gamble CompanySince its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. P&G sold its last remaining food brand, Pringles, to Kellogg in calendar 2012. Sales outside its home turf represent around 55% of the firm's consolidated total, with around one third coming from emerging markets.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Zacks Small Cap Research

    BICX: Pivotal trial underway

    By Beth Senko, CFA OTC:BICX READ THE FULL BICX RESEARCH REPORT After several years of research and preparation, subject enrollment and dosing is underway in the clinical trial of BioCorRx’s (OTC:BICX) subcutaneous naltrexone pellet (BICX104) for the treatment of opioid use (OUD) and alcohol use (AUD) disorders under the US FDA 505(b)(2) pathway. The phase 1, six-month open label trial is

  • GlobeNewswire

    BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at

  • GlobeNewswire

    BioCorRx Provides Business Update for the Second Quarter of 2022

    ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments. Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., commented, “During the quarter, we dosed the first subject in the Phase I clinical trial of BICX104, an implan

Advertisement
Advertisement